Alkermes Plc
NASDAQ:ALKS

Watchlist Manager
Alkermes Plc Logo
Alkermes Plc
NASDAQ:ALKS
Watchlist
Price: 31.27 USD -0.06% Market Closed
Market Cap: 5.2B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ALKS stock under the Base Case scenario is 26.78 USD. Compared to the current market price of 31.27 USD, Alkermes Plc is Overvalued by 14%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALKS Relative Value
Base Case
26.78 USD
Overvaluation 14%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.4
P/S
P/S
Price to Sales
3.4
vs History
36
vs Industry
68
Median 3Y
3.3
Median 5Y
3.3
Industry
6.9
Forward
3.7
More Details
14.7
P/E
P/E
Price to Earnings
14.7
vs History
15
vs Industry
9
Median 3Y
12.7
Median 5Y
-27.6
Industry
23
Forward
17.4
More Details
10
P/OCF
P/OCF
Price to OCF
10
vs History
87
vs Industry
12
Median 3Y
13.1
Median 5Y
30
Industry
19.7
More Details
10.7
P/FCFE
P/FCFE
Price to FCFE
10.7
vs History
69
vs Industry
3
Median 3Y
15.1
Median 5Y
16.3
Industry
22.8
More Details
3.4
P/B
P/B
Price to Book Value
3.4
vs History
60
vs Industry
25
Median 3Y
3.7
Median 5Y
3.6
Industry
2.6
More Details
2.8
EV/S
EV/S
Enterprise Value to Sales
2.8
vs History
50
vs Industry
61
Median 3Y
2.9
Median 5Y
2.8
Industry
7.4
Forward
3
More Details
3.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.3
vs History
50
vs Industry
62
Median 3Y
3.4
Median 5Y
3.4
Industry
9.3
More Details
10.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
10.2
vs History
36
vs Industry
11
Median 3Y
8.7
Median 5Y
8.5
Industry
4.1
Forward
12.9
More Details
10.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
10.9
vs History
14
vs Industry
10
Median 3Y
8.7
Median 5Y
-24.9
Industry
4.1
Forward
20.9
More Details
8.3
EV/OCF
EV/OCF
Enterprise Value to OCF
8.3
vs History
87
vs Industry
13
Median 3Y
11.4
Median 5Y
27.9
Industry
4.9
More Details
8.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
8.9
vs History
73
vs Industry
9
Median 3Y
11.9
Median 5Y
12.8
Industry
3.6
More Details
3.8
EV/IC
EV/IC
Enterprise Value to IC
3.8
vs History
7
vs Industry
34
Median 3Y
3.3
Median 5Y
3
Industry
4.7
More Details

Multiples Across Competitors

ALKS Competitors Multiples
Alkermes Plc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IE
Alkermes Plc
NASDAQ:ALKS
5.2B USD 3.4 14.7 10.2 10.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 853 448 -165 653.3 -201 155.9 -198 860.5
US
Abbvie Inc
NYSE:ABBV
330.7B USD 5.8 79.6 15.2 22.4
US
Amgen Inc
NASDAQ:AMGN
155.7B USD 4.6 26.2 14.2 23.3
US
Gilead Sciences Inc
NASDAQ:GILD
136.1B USD 4.7 22.8 9.9 13.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.7B USD 10.3 -116 24.6 25.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 021.3 -515.8 -561.6 -546.7
AU
CSL Ltd
ASX:CSL
119.3B AUD 5.1 28.1 17.3 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
52.8B USD 3.7 11.7 10.3 11.6
US
Seagen Inc
F:SGT
39.3B EUR 19.5 -59.7 -64.3 -58
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
39.6B USD 16.9 -146.8 -656.9 -329.2
P/S Multiple
Revenue Growth P/S to Growth
IE
Alkermes Plc
NASDAQ:ALKS
Average P/S: 3 168 685.7
3.4
-2%
N/A
FR
Pharnext SCA
OTC:PNEXF
34 853 448
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.6
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.7
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.3
10%
1
US
E
Epizyme Inc
F:EPE
2 021.3
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
3.7
5%
0.7
US
S
Seagen Inc
F:SGT
19.5
30%
0.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.9
29%
0.6
P/E Multiple
Earnings Growth PEG
IE
Alkermes Plc
NASDAQ:ALKS
Average P/E: 30.5
14.7
-12%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 653.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
79.6
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.2
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
22.8
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -116 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -515.8 N/A N/A
AU
CSL Ltd
ASX:CSL
28.1
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.7
7%
1.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -146.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IE
Alkermes Plc
NASDAQ:ALKS
Average EV/EBITDA: 14.5
10.2
-9%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 155.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.2
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.6
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.6 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.3
11%
0.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -656.9 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IE
Alkermes Plc
NASDAQ:ALKS
Average EV/EBIT: 18.5
10.9
-20%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 860.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.4
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.3
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.7
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.8
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -546.7 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.6
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -329.2 N/A N/A

See Also

Summary
ALKS intrinsic value, competitors valuation, and company profile.
DCF Valuation
ALKS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ALKS stock valuation using valuation multiples.
Wall Street Estimates
ALKS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ALKS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 259,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.